Dr. Geynisman on Patient Preferences for Treatment of RCC

Daniel M. Geynisman, MD
Published: Tuesday, Oct 31, 2017



Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).

According to Geynisman, patients are very motivated and interested in participating in clinical trials of immunotherapy.

Patients can derive tremendous benefit for a long time from immunotherapy, which is very different from most treatments, states Geynisman.
 
SELECTED
LANGUAGE


Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).

According to Geynisman, patients are very motivated and interested in participating in clinical trials of immunotherapy.

Patients can derive tremendous benefit for a long time from immunotherapy, which is very different from most treatments, states Geynisman.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x